Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282798 | 1.00 | IDO1 (0.48) | IDO1ADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL3156406 | 1.00 | IDO1 (0.48) | IDO1ADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL18548557 | 0.90 | ADRB3 (0.46) | IDO1ADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL29493206 | 0.90 | ADRB3 (0.46) | IDO1ADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL3922600 | 0.86 | LMNA (0.46) | IDO1ADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL3146631 | 0.86 | LMNA (0.46) | IDO1ADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL15771267 | 0.85 | ADRB3 (0.44) | IDO1ADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL14692667 | 0.85 | ADRB3 (0.44) | IDO1ADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL14402491 | 0.85 | ADRB1 (0.48) | IDO1ADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL10318241 | 0.85 | ADRB2 (0.44) | IDO1ADRB3ADRB1ADRB2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114958927-A | Method for preparing (S) -1- (3-chlorphenyl) -1, 3-propylene glycol | 尚科生物医药（上海）有限公司 | 2022-08-30 | — | — | CN | claimed |
| EP-1504014-B1 | PROCESS FOR PREPARATION OF CYCLIC PRODRUGS OF PMEA AND PMPA | METABASIS THERAPEUTICS INC (US) | 2015-12-02 | — | — | EP | claimed |
| US-20070203339-A1 | Process for Preparation of Cyclic Prodrugs of PMEA and PMPA | METABASIS THERAPEUTICS, INC. | 2007-08-30 | — | — | US | claimed |
| US-7193081-B2 | 9-(2-(2,4-cis(S)-4-(3-chlorophenyl)-2-oxo-1,3,2-dioxaphosphor-inan-2 -yl)methoxyethyl)adenine by coupling the dichloridate of 9-(2-phosphonyl- methoxyethyl- or propyl)adenine (PMEA)(PMPA) with a 1-(chlorophenyl) propylene-1,3-diol | METABASIS THERAPEUTICS, INC. (US) | 2007-03-20 | — | — | US | claimed |
| EP-1753762-A1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | Metabasis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1504014-A4 | PROCESS FOR PREPARATION OF CYCLIC PRODRUGS OF PMEA AND PMPA | METABASIS THERAPEUTICS INC (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005123729-A1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | METABASIS THERAPEUTICS, INC. (US) | 2005-12-29 | — | — | WO | claimed |
| EP-1504014-A2 | PROCESS FOR PREPARATION OF CYCLIC PRODRUGS OF PMEA AND PMPA | Metabasis Therapeutics, Inc. (US) | 2005-02-09 | — | — | EP | claimed |
| US-20030225277-A1 | Process for preparation of cyclic prodrugs of PMEA and PMPA | METABASIS THERAPEUTICS, INC. | 2003-12-04 | — | — | US | claimed |
| WO-2003095665-A2 | PMEA AND PMPA CYCLIC PRODUCING SYNTHESIS | METABASIS THERAPEUTICS, INC. (US) | 2003-11-20 | — | — | WO | claimed |
| US-12486292-B2 | Prodrug platform useful to deliver amines, amides and phenols | Changchun Changcheng Pharmaceutical Technology Co., LTD (CN) | 2025-12-02 | — | — | US | disclosed |
| CN-119954793-A | Compounds as xanthine oxidase inhibitors and uses thereof | 广州市联瑞制药有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119462766-A | Liver-targeting nitric oxide donor compound and application thereof | 深圳博瑞医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-114206894-B | Prodrug platform useful for delivery of amines, amides and phenols | 长春长乘医药科技有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2024199444-A1 | HETEROAROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翊维康医药有限责任公司 | 2024-10-03 | — | — | WO | disclosed |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-0451668-B1 | Process for the production of optically active alkyl 3-aryl-3-hydroxypropionates | CHISSO CORP (JP) | 1997-08-13 | — | — | EP | disclosed |
| US-5202457-A | Enzyme catalyzed transesterification, resolution of optical active alkyl 3-aryl-3-hydroxypropionate | CHISSO CORPORATION (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0451668-A2 | Optically active alkyl 3-aryl-3-hydroxypropionates and a method for producing thereof | CHISSO CORPORATION (JP) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225277-A1 | Process for preparation of cyclic prodrugs of PMEA and PMPA | MPO, PNP, MAOA | IDO1 3416/4885ADRB3 2909/4885ADRB1 2719/4885 |
| US-12486292-B2 | Prodrug platform useful to deliver amines, amides and phenols | GOT1, PAM, GLS2 | IDO1 577/4885ADRB3 1918/4885ADRB1 994/4885 |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | CCRL2, CCR4, ALK | IDO1 1693/4885ADRB3 338/4885ADRB1 1237/4885 |
| US-20070203339-A1 | Process for Preparation of Cyclic Prodrugs of PMEA and PMPA | PNP, PHOSPHO1, MPO | IDO1 3064/4885ADRB3 1959/4885ADRB1 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.